As previously reported, Credit Suisse analyst Martin Auster upgraded United Therapeutics to Outperform from Neutral and raised his price target on the shares to $101 from $98. The analyst sees downside as limited with multiple attributes that could support near-term stabilization/rebound, including potential for less aggressive generic uptake, greater recognition of steady Tyvaso/Orenitram cash flows with potential for strong Tyvaso tail value, ralinepag's potential best-in-class profile, potential for share buybacks, and potential for activism/M&A.